These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35410048)

  • 41. Upfront Xpert MTB/RIF for diagnosis of pediatric TB-Does it work? Experience from India.
    Kalra A; Parija D; Raizada N; Sachdeva KS; Rao R; Swaminathan S; Khanna A; Chopra KK; Hanif M; Singh V; Umadevi KR; Sheladia KN; Rao R; Vasundhara N; S A; A R N; Azeem A; Chhajlani V; Khurana J; Das NJ; Choudhury B; Nair SA; Mall S; Sen R; Chadha SS; Denkinger CM; Boehme C; Sarin S
    PLoS One; 2020; 15(8):e0236057. PubMed ID: 32756559
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prevalence of rifampicin resistant tuberculosis and associated factors among presumptive tuberculosis patients in a secondary referral hospital in Lagos Nigeria.
    Adejumo OA; Olusola-Faleye B; Adepoju V; Bowale A; Adesola S; Falana A; Owuna H; Otemuyiwa K; Oladega S; Adegboye O
    Afr Health Sci; 2018 Sep; 18(3):472-478. PubMed ID: 30602977
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rifampicin mono-resistance in Mycobacterium tuberculosis in KwaZulu-Natal, South Africa: a significant phenomenon in a high prevalence TB-HIV region.
    Coovadia YM; Mahomed S; Pillay M; Werner L; Mlisana K
    PLoS One; 2013; 8(11):e77712. PubMed ID: 24223122
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Enhancing TB case detection: experience in offering upfront Xpert MTB/RIF testing to pediatric presumptive TB and DR TB cases for early rapid diagnosis of drug sensitive and drug resistant TB.
    Raizada N; Sachdeva KS; Nair SA; Kulsange S; Gupta RS; Thakur R; Parmar M; Gray C; Ramachandran R; Vadera B; Ekka S; Dhawan S; Babre A; Ghedia M; Alavadi U; Dewan P; Khetrapal M; Khanna A; Boehme C; Paramsivan CN
    PLoS One; 2014; 9(8):e105346. PubMed ID: 25140877
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of the Xpert MTB/RIF on the detection of pulmonary tuberculosis cases and rifampicin resistance in Shanghai, China.
    Wu Z; Rueda ZV; Li T; Zhang Z; Jiang Y; Sha W; Yu F; Chen J; Pan Q; Shen X; Yuan Z
    BMC Infect Dis; 2020 Feb; 20(1):153. PubMed ID: 32070292
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Three year evaluation of Xpert MTB/RIF in a low prevalence tuberculosis setting: A Scottish perspective.
    Parcell BJ; Jarchow-MacDonald AA; Seagar AL; Laurenson IF; Prescott GJ; Lockhart M
    J Infect; 2017 May; 74(5):466-472. PubMed ID: 28237624
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Application of Xpert Mycobacterium tuberculosis/Rifampicin, Quantitative Polymerase Chain Reaction and High Resolution Melting Curve in the Diagnosis of Superficial Lymph Node TB.
    Han Y; Xiao N; Huang S; Qin M; Che N; Liu Z
    Curr Pharm Biotechnol; 2019; 20(12):1044-1054. PubMed ID: 31333119
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Frequency of MTB and rifampicin resistance MTB using Xpert-MTB/RIF assay among adult presumptive tuberculosis patients in Tigray, Northern Ethiopia: A cross sectional study.
    Wasihun AG; Dejene TA; Hailu GG
    PLoS One; 2020; 15(11):e0240361. PubMed ID: 33147218
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cost-benefit analysis of Xpert MTB/RIF for tuberculosis suspects in German hospitals.
    Diel R; Nienhaus A; Hillemann D; Richter E
    Eur Respir J; 2016 Feb; 47(2):575-87. PubMed ID: 26647440
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Performance evaluation of Xpert MTB/RIF in a moderate tuberculosis incidence compared with TaqMan MTB and TRCRapid M.TB.
    Tsuyuguchi K; Nagai H; Ogawa K; Matsumoto T; Morimoto K; Takaki A; Mitarai S
    J Infect Chemother; 2017 Feb; 23(2):101-106. PubMed ID: 27919693
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Upfront Xpert MTB/RIF testing on various specimen types for presumptive infant TB cases for early and appropriate treatment initiation.
    Raizada N; Khaparde SD; Rao R; Kalra A; Sarin S; Salhotra VS; Swaminathan S; Khanna A; Chopra KK; Hanif M; Singh V; Umadevi KR; Nair SA; Huddart S; Tripathi R; Surya Prakash CH; Saha BK; Denkinger CM; Boehme C
    PLoS One; 2018; 13(8):e0202085. PubMed ID: 30161142
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Algorithms for Screening for Active Tuberculosis among Individuals with Latent Tuberculosis Infection in a Rural Community in China.
    Xin H; Du Y; Cao X; Wang D; Zhang B; Zhang H; Feng B; He Y; He Y; Quan Z; Liu Z; Yan J; Guan L; Guan X; Shen F; Liu J; Jin Q; Pan S; Gao L
    Microbiol Spectr; 2022 Dec; 10(6):e0296722. PubMed ID: 36445141
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Age and sex distribution of Mycobacterium tuberculosis infection and rifampicin resistance in Myanmar as detected by Xpert MTB/RIF.
    Seifert M; Aung HT; Besler N; Harris V; Mar TT; Colman RE; Rodwell TC; Aung ST
    BMC Infect Dis; 2021 Aug; 21(1):781. PubMed ID: 34372793
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Is deployement of diagnostic test alone enough? Comprehensive package of interventions to strengthen TB laboratory network: three years of experience in Burkina Faso.
    Alagna R; Combary A; Tagliani E; Sawadogo LT; Saouadogo T; Diandé S; Ouedraogo F; Cirillo DM
    BMC Infect Dis; 2021 Apr; 21(1):346. PubMed ID: 33849486
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Diagnostic efficiency of Xpert MTB/RIF assay for osteoarticular tuberculosis in patients with inflammatory arthritis in China.
    Li Y; Jia W; Lei G; Zhao D; Wang G; Qin S
    PLoS One; 2018; 13(6):e0198600. PubMed ID: 29856840
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of Xpert MTB/RIF Ultra performance for pulmonary tuberculosis diagnosis on smear-negative respiratory samples in a French centre.
    Hodille E; Maisson A; Charlet L; Bauduin C; Genestet C; Fredenucci I; Rasigade JP; Lina G; Dumitrescu O
    Eur J Clin Microbiol Infect Dis; 2019 Mar; 38(3):601-605. PubMed ID: 30680567
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Association of Radiological Findings with the Xpert MTB/RIF Test in Patients with Suspected Pulmonary Tuberculosis.
    Neto WOE; Pereira GR; Barbosa MS; Dias NJD; Silva DR
    Lung; 2018 Dec; 196(6):755-760. PubMed ID: 30178313
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An evaluation of false-positive rifampicin resistance on the Xpert MTB/RIF.
    Cayci YT; Bilgin K; Coban AY; Birinci A; Durupınar B
    Mem Inst Oswaldo Cruz; 2017 Nov; 112(11):756-759. PubMed ID: 29091135
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Spectrum of Tuberculosis Disease in an Urban Ugandan Community and Its Health Facilities.
    Kendall EA; Kitonsa PJ; Nalutaaya A; Erisa KC; Mukiibi J; Nakasolya O; Isooba D; Baik Y; Robsky KO; Kato-Maeda M; Cattamanchi A; Katamba A; Dowdy DW
    Clin Infect Dis; 2021 Jun; 72(12):e1035-e1043. PubMed ID: 33283227
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting.
    Theron G; Peter J; van Zyl-Smit R; Mishra H; Streicher E; Murray S; Dawson R; Whitelaw A; Hoelscher M; Sharma S; Pai M; Warren R; Dheda K
    Am J Respir Crit Care Med; 2011 Jul; 184(1):132-40. PubMed ID: 21493734
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.